Aardvark Therapeutics (AARD) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Aardvark Therapeutics (AARD) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.45 of bullish evidence against -0.46 bearish.

Aardvark Therapeutics last closed at $5.04, -3.45% on the session.

Against the IVW growth benchmark the position is -4.06% over the forecast window.

The read is built from 13 underlying insights — 2 bullish and 11 bearish.

Agreement across those insights is 85%.

17 graded predictions for AARD so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Aardvark Therapeutics in the 14th percentile on return on equity, where 100 is best.

Aardvark Therapeutics is classified under Health Care / Pharmaceuticals, with a market capitalisation of $114.24M.

StockMap tracks Aardvark Therapeutics as the 93rd largest of the 142 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 61 Moderate Underperform, 57 Neutral, 19 Strong Underperform and 5 Moderate Outperform.

On that composite Aardvark Therapeutics ranks 98th of 142 in the group, against a group median of -0.24.